Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label extension study of dazukibart in idiopathic inflammatory myopathies
jRCT2031250053Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of dazukibart in Autoimmune Myopathies, dermatomyositis (DM) and polymyositis (PM), sponsored by Pfizer. Primary endpoints: Treatment-emergent adverse events, Clinically significant laboratory abnormalities and 4 more. Started Aug 2025; status: recruiting.
02
Drugs
dazukibart
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on jRCT2031250053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250053.